Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Research: Compendia: Research Models
Parkin-Null

Posted 18 April 2004

General Information

Inactivated mouse parkin gene using a pPN2T plasmid with neomycin cassette and two TK gene selection cassettes. In this construction, the Parkin gene was interrupted by the neomycin resistance cassette within exon 3. The first 62 nucleic acids of exon 3 were preserved. The introduced deletion covers an area of 1097 bp, encompassing the last 179 nucleic acids of exon 3 and the first 918 nucleic acids of intron 3. Homologous vector was electroporated into 129SV ES CK35 cells. 2 resulting clones were microinjected into blastocysts from C57/Bl6 mice. Germ line transmission was obtained.

Phenotype

Neuropathological analysis:

Cognitive deficits, inhibition of amphetamine-induced dopamine release and inhibition of glutamate synaptic transmission. The levels of endogenous dopamine are increased in the limbic brain areas of parkin mutant mice and there is a shift towards increased metabolism of dopamine by MAO. There was no evidence of loss of nigrostriatal dopamine neurons. However, the level of dopamine transporter protein was reduced in these animals.

Behavioral:

The parkin mutant mice are viable and reproduce successfully, but display abnormal baseline motor activity. Also display decreased body weight and temperature.

Availability

Thomas A. Rooney
Aventis Pharma SA
13 Quai Jules Guesde, F-94400
Vitry-sur-Seine, France
Telephone: 33 158932645
Email: thomas.rooney@aventis.com

Reference

Primary:

Itier JM, Ibanez P, Mena MA, et al. Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum Mol Genet 2003; 12: 2277-2291 Abstract




Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark

See recent updates
Alzheimer's Disease Mouse Model Resource
Considerations for Choosing Controls
Research Tools

Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad